Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 2, 2003, Pages 219-222

  Päivä, Hannu ^a   Laakso, Juha ^b   Lehtimäki, Terho ^a   Isomustajärvi, Marja ^a   Ruokonen, Inkeri ^b   Laaksonen, Reijo ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Asymmetric dimethylarginine; Cholesterol; Nitric oxide; Statins

Indexed keywords

ARGININE DERIVATIVE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOMETHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANALYSIS OF VARIANCE; ARGININE; AZO COMPOUNDS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE;

EID: 12244290991     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200302000-00010     Document Type: Article

References (11)

1. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res. 1999;15:542-8. Review.
2. Babu BR, Griffith OW. Design of isoform-selective inhibitors of nitric oxide synthase. Curr Opin Chem Biol. 1998;2:491-500.
3. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-7.
4. Bode-Böger SM, Böger, RH, Kienke S, et al. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun. 1996;219:598-603.
5. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-6.
6. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33:652-8.
7. Goonasekera CD, Shah V, Rees DD, et al. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press. 2000;9:16-21.
8. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events in relation to concentration of serum asymmetrical dimethylarginine. Lancet. 2001;358:2127-8.
9. Vishwanathan K, Tackett RL, Stewart JT, et al. Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000;748:157-66.
10. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-35.
11. Cardinale CP, Fard A, Eisenberg MS, et al. Elevated plasma level of asymmetric dimethylarginine (ADMA) is associated with atherosclerotic disease of the thoracic aorta [abstract]. J Am Coll Cardiol. 2001;37(suppl A):648A.